Nobel-prize caliber technology, a powerful and flexible
intra/trans dermal delivery platform, a game-changing
infection-control product, and a world-class management team

Microdermis Corporation is a nimble life sciences company with an innovative Amidermal® dermatological delivery platform. Microdermis’ business focuses on development of novel over-the-counter products that combine known, proven active ingredients with its unique Amidermal® delivery system to produce compelling products with significantly-enhanced performance, low manufacturing costs, and rapid time-to-market. Microdermis’ flagship product, Provodine®, is a groundbreaking infection-control product that clearly demonstrates the power and flexibility of the Amidermal® platform. Microdermis has a full pipeline of further products in active development that will follow closely behind the commercial roll-out of Provodine®. Microdermis actively targets both military and civilian applications of its technologies, both in the US and abroad, as it builds its commercial infrastructure and sales network.

The Amidermal® Platform
Microdermis’ foundation Amidermal® technology is based on over a decade of research and development inspired by Nobel Laureate Dr. Joshua Lederberg, a renowned US molecular biologist. The Amidermal® technology enables precise targeted delivery of active agents to, into, and through the layers of the skin. The fundamental chemistry of the Amidermal® system is extremely skin-friendly with ingredients that moisturize and nourish the skin, enhancing user comfort and compliance. The precise control of the depth of penetration, remarkable persistence, and very skin-friendly properties are the hallmark of products built upon this market-changing Amidermal® platform. These properties can provide significantly enhanced performance using well-known, proven active ingredients (as seen by the remarkable performance of Provodine® compared to other PVP-I-based products) as well as with new emerging APIs. This combination of drug and delivery system can enable groundbreaking new products with streamlined regulatory pathways at compelling manufacturing costs. The inherent flexibility of the Amidermal® platform allows widespread applicability to a number of product areas, including both the professional healthcare and personal care markets. To date, several pharmaceutical and personal care companies have entered into licensing arrangements with Microdermis, in areas ranging from fine fragrances to incontinence care and several positions in between.

Provodine®
Provodine®—Microdermis’ initial commercial product—is a next-generation professional antiseptic that meets or exceeds FDA requirements for use as a Surgical Scrub, Pre-Operative Skin Preparation, Healthcare Personnel Hand Wash and First Aid Antiseptic. Microdermis’ unique Amidermal® technology enables significantly enhanced kill strength, killing the most dangerous microbes. There are currently no known resistant strains to Provodine®, making it especially useful for deployment in challenging environments with an unknown mix of infection sources, such as in military field hospitals and with globally-deployed NGO personnel. The Amidermal® technology also extends the potency window of the active ingredient, with persistence exceeding 6 hours. All of this remarkable antimicrobial performance comes in a surprisingly skin-friendly lotion. Provodine® contains a proprietary blend of ingredients that nourish and rebuild the skin, eliminating dryness and cracking, which are not only uncomfortable, but also create portals for microbes. Healthy skin leads to better compliance with hand hygiene protocols. The remarkable performance of Provodine® has been demonstrated in a comprehensive series of tests and trials, both laboratory-based and in real-world clinical settings. Provodine® is undergoing continuous testing to establish further evidence of its market-disruptive capabilities.

Microdermis Management
Leading the Microdermis team is its CEO, Mac Sweeney, who is a former U.S. Congressman and 30+ year business turnaround expert and private equity professional. He was a pioneer when he was elected to the U.S. Congress and appointed to the White House staff while still in his 20s. Following his political career, Mac Sweeney went on to early work as a Wall Street lawyer before captaining eight business turnarounds and startups and heading multiple business restructurings. He has led equity capital raises and large infrastructure project funding. He has built a world-class management team at Microdermis, consisting of experienced scientists, medical professionals, and experienced global leaders. The team is well-positioned for its aggressive commercial launch of Provodine® and future products, especially in the U.S. and Latin America.

Microdermis History

What is now Microdermis Corporation began in a Florida research institute with investments from 42 doctors and angel-investors. The IP is derived in part from the predecessor-company’s inspirational work that was partially funded (before being wholly acquired in 2009) by Microdermis’ founder.

Microdermis was formed in October 2010 and the turnaround, from a medical doctor-run enterprise to a refinanced and recapitalized viable business entity, was concluded in early 2011. The scientific, management, medical and technical leadership began functioning as a corporate team by mid-2011.

Organization and Management

Microdermis is a C-Corporation organized under the laws of the State of Delaware. The Company’s day to day operations are overseen by its management team, which reports to the Company’s Board of Directors. Microdermis’ management team utilizes a matrix management structure with cross-functional teams assigned to achieve each of Microdermis’ objectives. These cross-functional teams are ultimately responsible to the Company’s Chief Executive Officer, and are subject to “big picture” oversight by the Company’s Board of Directors.

Key Management Bios

Mac Sweeney
Chief Executive Officer
Mac Sweeney is a 30+ year business turnaround expert and private equity professional with international experience. A pioneer when elected to the U.S. Congress and appointed to the White House staff while still in his 20s, Mac Sweeney went on to early work as a Wall Street lawyer before captaining eight business turnarounds & startups and heading multiple business restructurings. He has led equity capital raises and large infrastructure project funding.

Peter Lentini
EVP & Chief Science Officer
A 25+ year industry veteran whose career originated with Purdue Pharma, Peter Lentini advanced in his profession as a chief chemist and commercialization guru by heading New Ventures Research and Development Lab for Estee Lauder. Included in his technical success story are nearly 1000 new product developments and 29 patents for dermatological technologies that range from antiseptics to sunscreens to “disruptive” product delivery systems. His extensive skillset ranges from new raw material development through innovative finished goods, including dermatological preparations, professional antiseptics, sun care and skincare line development, to clinical and advertising claim support.

Thomas M. McGinn
Sr. VP - Finance
A seasoned, hands-on finance and operations professional, Tom McGinn also boasts extensive domestic and international experience including 8 years in the healthcare industry, the effective completion of three business turnarounds. He joins several members of the Management Team from these prior shared business successes. Tom is to lead the organization and implementation of the company’s clinical trial programs. Microdermis has entered talks with multiple entities, domestic and abroad, for the purpose of enacting more widespread clinical trials of its products. In the Andean region of South America, Tom is overseeing clinical testing in Chile, Ecuador, and Peru. Tom has and continues to be a valuable member of the Microdermis management team and aims, through his new responsibilities, to totally and completely validate the integrity and superiority of Microdermis products and technology in the skin-care field. His continued work will be a key driver of the enterprise going forward for Microdermis.

Rafael Jaque Fischer
Sr. VP and Director, Latin American Business Operations
Rafael M. Jaque Fischer joined Microdermis as Vice President of Latin American Business Operations. Based in Ecuador, Rafael is a business expert with 25 years of experience working with Latin American markets and government officials. His skills include business, politics, and conflict resolution, and he has worked as an analyst in said fields. His connections and time spent for Microdermis have been invaluable to opening markets for testing and distribution throughout Microdermis’ now-active South American regions. Rafael has worked for many notable international organizations, including the UN Economic and Social Council, UNESCO, UNHCR, the Andean Parliament, the Latin American Parliament, and the European Union. His skills and experience reach far in the business world, political spheres, and as a strong linguist (Spanish, English, French). His aid has been and continues to be of great value to Microdermis on many fronts, most notably, the Latin American.

Harry Corless
VP Tech Ops
Harry is a 30+ year veteran of the Pharmaceutical and Consumer Products industries, having served in leadership roles within manufacturing and supply chain. He started his career in pharmaceutical Quality Assurance before moving into manufacturing and supply chain operations, working his way up to Head of Worldwide Operations for the Block Drug Company, Inc. As Head of Worldwide Operations and Supply Group, Harry managed a network of 8 plants servicing the sales and marketing efforts in 23 countries. With his diverse background, Harry has led or contributed to teams responsible for launching hundreds of Drugs and Medical Devices, and has managed teams through times of explosive growth, maintaining high standards of customer service and quality.

Governance

Microdermis is a C-Corporation organized under the laws of the State of Delaware. The Company’s day-to-day operations are overseen by its management team, which reports to the Company’s Board of Directors. Microdermis’ management team utilizes a matrix management structure with cross-functional teams assigned to achieve each of Microdermis’ objectives. These cross-functional teams are ultimately responsible to the Company’s Chief Executive Officer, and are subject to “big picture” oversight by the Company’s Board of Directors.

Board of Directors

Rear Admiral James Johnson, M.D.
Chairman
After nearly 40 years of service in the United States Navy Medical Corps, Admiral Johnson has served as an independent consultant for a variety of companies focusing on bio-science, health information management and development, and medical devices. At Naval Hospital Camp Pendleton in California, he held a progression of assignments including Staff Surgeon; Chairman, Department of Surgery; and Director of Surgical Services. In 1989, he was transferred to Washington, D.C., where he held the position of Deputy Chief of the Medical Corps. His experience includes a long and diverse history of roles including Principal Director for Clinical and Program Policy in the Office of the Assistant Secretary of Defense for Health Affairs. Rear Admiral Johnson assumed his duties as the Regional Director of TRICARE Regional Office-West (TRO-West) in November 2003, the first of three Regional Directors to be named, overseeing health care contracts and the health care delivery system in twenty states with more than 2,000,000 TRICARE eligible beneficiaries. He has advised the Commandant of the Marine Corps headquarters staff agencies on all matters affecting medical and dental support for the Marine Corps. Rear Admiral Johnson earned his undergraduate degree in Biology/Chemistry at Oberlin College in Oberlin, Ohio, and his Medical Degree at the University of Rochester in Rochester, N.Y.

Daniel Bradbury
Director
Mr. Bradbury serves as a board member for Illumina, Corcept, Geron, Castle Biosciences, and several educational and nonprofit entities, including the Keck Graduate Institute and the UCSD Rady School of Management. Mr. Bradbury is the managing member of BioBrit, LLC, a life science consulting and investment firm. After holding a number of sales and marketing positions at SmithKline Beecham, he became President, CEO and a director of Amylin Pharmaceuticals, leading them to a very successful exit in 2012, for which he was recognized as a Director of the Year (Creating Shareholder Value) by the Corporate Directors Forum (San Diego) later in 2012. Mr. Daniel Bradbury holds a B.Pharm. and Diploma in Management Studies.

James Hosler, M.D.
Director
Having received his undergraduate and medical degrees from the University of Michigan, Jim Hosler went on to a successful career as a gastroenterologist, culminating in the management of his own practice in Texas. Jim provided early seed funding for the company and helped to recruit and organize the management team.

Mac Sweeney
Director
See Chief Executive Officer profile.

Military Medical & Marketing Council ("M3C")

In support of Microdermis’ military strategy, the Military Medical & Marketing Council (“M3C”) was formed with top-level (2, 3 and 4-star Generals/Admirals) retired-military leadership, with a combined 212 years of experience in medical research, healthcare, combat, procurement, and/or logistics. The M3C’s medical and scientific expertise, leadership, and management expertise have been instrumental in developing and executing our military marketing strategy.

Lieutenant General Paul K. Carlton, MD, United States Air Force (Retired)
Clinical Trials Implementation
Lieutenant General Carlton was the 17th Surgeon General of the U.S. Air Force. During his command of the 1702nd Air Refueling Wing Contingency Hospital while deployed to Southwest Asia in support of Operation Desert Shield and Desert Storm, Lieutenant General Carlton completed 32 combat support missions and 140 combat flying hours in the C-21, C-130, KC-10 and KC-135. Lieutenant General Carlton was awarded the Airman’s Medal for heroism by voluntarily risking his life at the Pentagon, Washington, D.C. on 11 September 2001. He was the architect for the change in the treatment of the war wounded that has created the best survival in the history of war. He did this by moving surgery far forward, created a transportation system that can move the critical injured across long distances, and emphasizing the necessity for continuous training for war.

Lieutenant General Carlton is a distinguished graduate of the U.S. Air Force academy. He attended the University of Colorado in Denver, Colorado, where he received his Doctor of Medicine degree and completed his General Surgery Residency at Wilford Hall Medical Center at Lackland AFB, Texas. As a surgeon, Lieutenant General Carlton performed more than 4,000 operations as principal surgeon and 6,000 as first assistant. As a consultant in general surgery to the Air Force Surgeon General, he conceptualized and implemented the first Air Force rapid-response surgical team in Europe—the flying ambulance surgical trauma team. Lieutenant General Carlton’s commands and assignments during his service in the U.S. Air Force include: Chief of General Surgery at the U.S. Air Force Hospital at Luke AFB, Arizona; Chairman of the Department of Surgery at the U.S. Air Force Regional Medical Center at Wiesbaden AB, West Germany; Commander of the U.S. Air Force Hospital at Torrejon AB, Spain; Commander of the U.S. Air Force Medical Center at Scott AFB, Illinois. Lieutenant General Carlton also served as the Director of Medical Services and Training with Headquarters Air Education and Training Command at Randolph AFB, TX, as Commander of the 59th Medical Wing at Wilford Hall Medical Center at Lackland AFB, as Commander and Director of the Air Force Medical Operations Agency in the Office of the Surgeon General at Bolling AFB, Washington, D.C.

Lieutenant General Carlton’s deep understanding of clinical trial development and implementation, evidence and outcomes based medicine, medical readiness, and hospital preparedness are critical as Microdermis executes its Clinical Trials Implementation strategy. Currently, Lieutenant General Carlton serves as Adjunct Professor of Surgery at USUHS, Director at the Office of Innovation and Preparedness for the TX A&M University System Health Science Center, and Preparedness Consultant for several organizations.

Major General Lester Martinez-Lopez, MD, United States Army (Retired)
M3C R&D Advisory
Dr. Martinez-Lopez currently serves on a variety of boards and advisory groups in the healthcare and medical industries. He has served as Chief Medical Officer at Brandon Regional Hospital in Brandon, Florida and Senior Vice-President & Administrator of the Lyndon B. Johnson General Hospital in Houston, Texas. He is a diplomat of the American Board of Family Practice and the American Board of Preventive Medicine.

Dr. Martinez-Lopez was as the first Hispanic to head the Army Medical Research and Materiel Command (MRMC) at Fort Detrick, Maryland. As the Commander, he oversaw a complex structure with six major research laboratories: the U.S. Army Medical Research Institute of Infectious Diseases, the Walter Reed Army Institute of Research, the U.S. Army Medical Research Institute of Chemical Defense, the U.S. Army Aeromedical Research Laboratory, the U.S. Army Institute of Surgical Research and the U.S. Army Research Institute of Environmental Medicine. Dr. Martinez-Lopez retired from the U.S. Army in 2005 after 28 years of service.

In 1978, Dr. Martinez-Lopez graduated from the School of Medicine in the University of Puerto Rico and later completed his Masters in Public Health from Johns Hopkins University, where he received the Woodrow Wilson Award for Distinguished Government Service. While he was the Commander of the MRMC, Dr. Martinez-Lopez’s responsibilities included directing the U.S. Army’s worldwide medical research, acquisition, and logistics program. Dr. Martinez-Lopez also commanded three distinct hospitals, where he oversaw the military health support during Hurricane Mitch in Central America, and served as the Chief Medical Officer of the United Nation’s Mission in Haiti.

Dr. Martinez-Lopez’s in-depth understanding of infectious diseases, medical research, public health, medical research, and corporate governance continue to prove instrumental as Microdermis develops and executes its marketing strategies.

Medical Advisory Board

Microdermis, an emerging biotechnology company focused on the prevention and control of infectious diseases, announces the establishment of a Medical Advisory Board (MAB), which includes a Biodefense Work Group (BWG). Microdermis will engage the MAB members to actively collaborate on the research and development of Provodine, its next-generation antiseptic, and explore further use of its patented Amidermal delivery platform. Members of the MAB are distinguished scientists and clinicians who provide guidance to Microderrmis based on their respective areas of expertise.

James Hosler, MD, FACP
MAB Co-Chairman
Dr. Hosler received his undergraduate and medical degrees from the University of Michigan and subsequently did his Internal Medicine Residency and Fellowships in Gastroenterology and Clinical Pharmacology at Kansas University Medical Center. During that period he was involved in numerous Phase I and Phase II pharmaceutical trials. Once in private practice in Dallas-Ft. Worth, he established one hospital-based GI Lab, and then his own outpatient Ambulatory Surgical Center, and he managed both over 29 years. During that time he also participated in multiple Phase III drug trials.

Dr. Hosler is a prior Board Chairman and a current Director of Microdermis. He provided early seed funding for the company and was instrumental in the management team recruitment.

Lieutenant General Paul K. Carlton, MD, United States Air Force (Retired)
Biodefense Work Group
Lieutenant General Carlton was the 17th Surgeon General of the U.S. Air Force. During his command of the 1702nd Air Refueling Wing Contingency Hospital while deployed to Southwest Asia in support of Operation Desert Shield and Desert Storm, Lieutenant General Carlton completed 32 combat support missions and 140 combat flying hours in the C-21, C-130, KC-10 and KC-135. Lieutenant General Carlton was awarded the Airman’s Medal for heroism by voluntarily risking his life at the Pentagon, Washington, D.C. on 11 September 2001. He was the architect for the change in the treatment of the war wounded that has created the best survival in the history of war. He did this by moving surgery far forward, created a transportation system that can move the critical injured across long distances, and emphasizing the necessity for continuous training for war.

Lieutenant General Carlton is a distinguished graduate of the U.S. Air Force academy. He attended the University of Colorado in Denver, Colorado, where he received his Doctor of Medicine degree and completed his General Surgery Residency at Wilford Hall Medical Center at Lackland AFB, Texas. As a surgeon, Lieutenant General Carlton performed more than 4,000 operations as principal surgeon and 6,000 as first assistant. As a consultant in general surgery to the Air Force Surgeon General, he conceptualized and implemented the first Air Force rapid-response surgical team in Europe—the flying ambulance surgical trauma team. Lieutenant General Carlton’s commands and assignments during his service in the U.S. Air Force include: Chief of General Surgery at the U.S. Air Force Hospital at Luke AFB, Arizona; Chairman of the Department of Surgery at the U.S. Air Force Regional Medical Center at Wiesbaden AB, West Germany; Commander of the U.S. Air Force Hospital at Torrejon AB, Spain; Commander of the U.S. Air Force Medical Center at Scott AFB, Illinois. Lieutenant General Carlton also served as the Director of Medical Services and Training with Headquarters Air Education and Training Command at Randolph AFB, TX, as Commander of the 59th Medical Wing at Wilford Hall Medical Center at Lackland AFB, as Commander and Director of the Air Force Medical Operations Agency in the Office of the Surgeon General at Bolling AFB, Washington, D.C.

Lieutenant General Carlton’s deep understanding of clinical trial development and implementation, evidence and outcomes based medicine, medical readiness, and hospital preparedness are critical as Microdermis executes its Clinical Trials Implementation strategy. Currently, Lieutenant General Carlton serves as Adjunct Professor of Surgery at USUHS, Director at the Office of Innovation and Preparedness for the TX A&M University System Health Science Center, and Preparedness Consultant for several organizations.

Major General Lester Martinez-Lopez, MD, United States Army (Retired)
Biodefense Work Group
Dr. Martinez-Lopez currently serves on a variety of boards and advisory groups in the healthcare and medical industries. He has served as Chief Medical Officer at Brandon Regional Hospital in Brandon, Florida and Senior Vice-President & Administrator of the Lyndon B. Johnson General Hospital in Houston, Texas. Dr. Martinez-Lopez was the first Hispanic to head the Army Medical Research and Materiel Command (MRMC) at Fort Detrick, Maryland. As the Commander, he oversaw a complex structure with six major research laboratories: the U.S. Army Medical Research Institute of Infectious Diseases, the Walter Reed Army Institute of Research, the U.S. Army Medical Research Institute of Chemical Defense, the U.S. Army Aeromedical Research Laboratory, the U.S. Army Institute of Surgical Research and the U.S. Army Research Institute of Environmental Medicine. Dr. Martinez-Lopez retired from the U.S. Army in 2005 after 28 years of service. In 1978, Dr. Martinez-Lopez graduated from the School of Medicine in the University of Puerto Rico and later completed his Masters in Public Health from Johns Hopkins University, where he received the Woodrow Wilson Award for Distinguished Government Service. Dr. Martinez-Lopez also commanded three distinct hospitals, where he oversaw the military health support during Hurricane Mitch in Central America, and served as the Chief Medical Officer of the United Nation’s Mission in Haiti. He is a diplomat of the American Board of Family Practice and the American Board of Preventive Medicine.

Dr. Martinez-Lopez also serves on the Military Medical Marketing Council for Microdermis.